A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Duarte, California.

Sponsor
AstraZeneca
Study ID
NCT07681596
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD4045 — BIOLOGICAL
    Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)
  • Daratumumab — DRUG
    Anti-CD38 monoclonal antibody
  • Aldesleukin — DRUG
    Recombinant human IL-2

Study Details

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Key Dates

First listed
Jul 2, 2026
Start date
Jul 27, 2026
Status verified
Aug 2026
Primary completion
Mar 6, 2031
Completion
Mar 6, 2031

Study Design

Enrollment
101 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Module 1: AZD4045 monotherapy
  • Experimental: Module 1: AZD4045 in association with daratumumab and aldesleukin

Primary Outcome Measure

Adverse events (AEs) and serious AEs (SAEs) [ Time Frame: Through study completion, an average of 2 years ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Research SiteDuarteCalifornia91010-
Research SiteDenverColorado80218-
Research SiteTampaFlorida33612-
Research SiteAtlantaGeorgia30322-
Research SiteSt LouisMissouri63110-
Research SiteHackensackNew Jersey07601-
Research SiteClevelandOhio44195-
Research SiteNashvilleTennessee37203-
Research SiteHoustonTexas77030-
Research SiteMilwaukeeWisconsin53226-

Related Studies